Prelude Therapeutics (Prelude Therapeutics) Cash-to-Debt : 13.79 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prelude Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prelude Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 13.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prelude Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Prelude Therapeutics's Cash-to-Debt or its related term are showing as below:

PRLD' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.79 Med: 138.74 Max: No Debt
Current: 13.79

During the past 6 years, Prelude Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 13.79. And the median was 138.74.

PRLD's Cash-to-Debt is ranked better than
60.13% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs PRLD: 13.79

Prelude Therapeutics Cash-to-Debt Historical Data

The historical data trend for Prelude Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Prelude Therapeutics Cash-to-Debt Chart

Prelude Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

73.17

No Debt

167.38

110.11

13.79

Prelude Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															110.11	123.92	271.84	485.28	13.79

Competitive Comparison of Prelude Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Prelude Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prelude Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Prelude Therapeutics's Cash-to-Debt falls into.

Prelude Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Prelude Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	232.935	/	(1.481	+	15.407)
	=	13.79

Prelude Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	232.935	/	(1.481	+	15.407)
	=	13.79

Prelude Therapeutics (NAS:PRLD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Prelude Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Prelude Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Prelude Therapeutics (Prelude Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prelude Therapeutics Inc (NAS:PRLD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Powder Mill Road, Wilmington, DE, USA, 19803

Website

https://www.preludetx.com

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Executives

Krishna Vaddi	director, officer: President, CEO	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Bryant David Lim	officer: Chief Legal Counsel, Corp Sec.	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Laurent Chardonnet	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jane Huang	officer: President, CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Deborah Morosini	officer: EVP, Chief of Clinical Affairs	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
Andrew Combs	officer: EVP, Head of Chemistry	C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON DE 19803
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977